

GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED CIN: L85110GJ2012PLC068700

REGD OFFICE: GLOBAL HOSPITAL, OPP. AUDA GARDEN, NR. WATER TANK, BODAKDEV, AHMEDABAD - 380054, GUJARAT.

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED AND YEAR ENDED ON MARCH 31, 2023

(Rs. in	Lakhs	except	per s	hare d	ata)
---------	-------	--------	-------	--------	------

		(Rs. in Lakhs except per share data)					
Sr.	20 8 9	Half Year Ended			Year Ended		
No.	Particulars	31-03-2023	30-09-2022	31-03-2022	31-03-2023	31-03-2022	
		Audited	Unaudited	Audited	Audited	Audited	
1	INCOME						
	Revenue from Operations	1,170.22	1,179.95	1,287.30	2,350.17	3,281.54	
	Other Income	17.06	6.81	16.10	23.87	22.79	
	Total Income	1,187.27	1,186.77	1,303.40	2,374.04	3,304.33	
2	EXPENSES						
	Direct Expenses	389.26	525.76	628.03	915.02	1,364.18	
	Purchase of Stock-in-Trade	372.72	53.73	91.36	426.45	367.51	
	Changes in inventories of finished goods, work in progress and stock in trade	(47.62)	54.35	8.26	6.73	(7.06)	
	Employee benefits expenses	181.40	181.61	235.32	363.02	406.06	
	Finance Costs	19.64	20.41	130.70	40.05	139.89	
	Depreciation and amortisation expenses	58.97	57.68	56.84	116.65	114.37	
	Other Expenses	48.51	186.84	198.46	235.35	348.37	
	Total Expenses	1,022.89	1,080.38	1,348,98	2,103.27	2,733.32	
3	Profit/(Loss) before exceptional and extrordinary items and tax (1 - 2)	164;39	106.39	(45.58)	270.78	571.01	
4	Exceptional Items	-		-	-	-	
5	Profit/(Loss) before extraordinary item and tax (3 - 4)	164.39	106.39	(45.58)	270.78	571.01	
_	Extraordinary Items	104.39	100.59	(43.36)	270.70	571101	
6	The service between the service and the servic	164,39	106.39	(45.58)	270.78	571.01	
7	Profit/(Loss) before tax (5 - 6)	104.39	100.39	(43,36)	2/0./6	3/1.01	
8	Tax Expense	27.14	17.76	(2.61)	45.20	95.30	
	a) Current tax	27.44	17.76	(7.61)	45.20	118.32	
	b) Deferred tax	29.94	12.80	(28.32)	42.73	110.32	
	c) Excess/(Short) Provision Of Income Tax	0.10	-	-	0.10	-	
9	Net Profit/(Loss) from continuing activities after tax (7 - 8)	106.91	75.84	(9.65)	182.75	357.39	
10	Net Profit/(Loss) from discontinued operations before tax	-	•	-	-	-	
11	Tax Expense of discontinued operations	-	-	-	-	-	
12	Net Profit/(Loss) from discontinued operations after tax (10-11)	-		-			
13	Net Profit/(Loss) for the period after tax (9 + 12)	106.91	75.84	(9.65)	182.75	357.39	
14	Other Comprehensive Income, net of tax (OCI)						
	a) Items that will not be reclassified to profit or loss						
	b) Income tax relating to items that will not be reclassified to profit or loss						
	Total						
15	Total Comprehensive Income for the period (13+14)	106.91	75.84	(9.65)	182.75	357.39	
16	and the state of t	1.050.00	1.050.00	700.00	1.050.00	700.00	
	Paid-up Equity Share Capital	1,050.00	1,050.00	700.00	1,050.00	700.00	
17	Face Value of Equity Share Capital	10.00	10.00	10.00	5.378.97	996.22	
17	Reserves excluding revaluation reserves	1.05	0.74	(0.14)		5.11	
18	Basic earning (loss) per share (Not Annualised for half year ended)	1.05	0.74	(0.14)		5.11	
19	Diluted earning (loss) per share (Not Annualised for half year ended)	0.14	0.74	0.51	0.14	0.17	
	Debt Equity Ratio	667.08	4.80	0.31	0.14	3.01	
-	Debt Service Coverage Ratio Interest Service Coverage Ratio	667.08	24.76	1.19	54.51	8.32	

For, Global Longlife Hospital and Research Limited

Dhruv Jani Managing Director DIN: 03154680

Date: 30.05.2023 Place: Ahmedabad



A division of

Global Longlife Hospital & Recreensal Longlife Hospital and Research Limited CIN: L85110GJ2012PLC068700

 $REGD\ OFFICE:\ GLOBAL\ HOSPITAL,\ OPP.\ AUDA\ GARDEN,\ NR.\ WATER\ TANK,\ BODAKDEV,\ AHMEDABAD-380054,\ GUJARAT.$

AUDITED STATEMENT OF ASSETS AND LIABILITIES

	Particulars	As At 31-03-2023	As At 31-03-2022
	Tal (tealing)	Audited	Audited
	I		
1	Equity and liabilities		
1	Shareholders' funds	1,050.00	700.0
	Share capital	5,378.97	996.2
	Reserves and surplus	5,378.97	990.2
	Money received against share warrants Total shareholders' funds	6,428.97	1,696.2
	Total shareholders funds	0,428.97	1,090.2
2	Share application money pending allotment		
3	Deferred government grants		
4	Minority interest		
5	Non-Current Liabilities		
	Long-term borrowings	364.23	282.
	Deferred tax liabilities (net)	303.40	2021
	Foreign currency monetary item translation difference		
	liability account		
	Other long-term liabilities	8.64	36.
	Long-term provisions	8.01	5.
	Total Non-Current Liabilities	380.88	323.
		20000	0001
6	Current Liablities		407
	Short-term borrowings	565.25	587.
	Trade Payables		
	(A) Total outstanding dues of micro enterprises and		A Million and
	small enterprises.	59.30	
	(B) Total outstanding dues of creditors other than micro		
	enterprises and small enterprises.		
	emerprises and small emerprises:	71.79	427.
	Other current liabilities	40.21	237.
		47.42	124.
	Short-term provisions	783.98	1,377.
	Total current liabilities Total equity and liabilities	7,593.83	3,397.
	Total equity and habilities	7,075105	3,3711
	Assets		
1	Non-current assets		
(i)	Fixed assets		
1-/	Tangible assets	1,651.50	1,670
	Producing properties	1,123.00	
	Intangible assets	0.62	0
	Preproducing properties	V.102	
	Tangible assets capital work-in-progress		
	rangiole assets capital work-in-progress		
		102.98	the second secon
	Intangible assets under development or work-in-		
	progress		resulting the second se
		1,755.10	1,671.
	I otal fixed assets		10
(ii)	Non-current investments	10.00	10
	Non-current investments		
	Non-current investments Deferred tax assets (net)	10.00 214.47	
(ii) (iii) (iv)	Non-current investments		
(iii) (iv)	Non-current investments Deferred tax assets (net) Foreign currency monetary item translation difference asset account		257
(iii) (iv) (v)	Non-current investments Deferred tax assets (net) Foreign currency monetary item translation difference asset account Long-term loans and advances	214.47	257
(iii) (iv) (v)	Non-current investments Deferred tax assets (net) Foreign currency monetary item translation difference asset account		
(iii) (iv) (v) (vi)	Non-current investments Deferred tax assets (net) Foreign currency monetary item translation difference asset account Long-term loans and advances Other non-current assets Total non-current assets	2,261.44	257
(iii) (iv) (v)	Non-current investments Deferred tax assets (net) Foreign currency monetary item translation difference asset account Long-term loans and advances Other non-current assets Current assets	2,261.44	257
(iii) (iv) (v) (vi)	Non-current investments Deferred tax assets (net) Foreign currency monetary item translation difference asset account Long-term loans and advances Other non-current assets Total non-current assets Current assets Current investments	2,261.44 2,485.91	257 324 591
(iii) (iv) (v) (vi)	Non-current investments Deferred tax assets (net) Foreign currency monetary item translation difference asset account Long-term loans and advances Other non-current assets Total non-current assets Current assets Current investments Inventories	2,261.44 2,485.91	324 591
(iii) (iv) (v) (vi)	Non-current investments Deferred tax assets (net) Foreign currency monetary item translation difference asset account Long-term loans and advances Other non-current assets Total non-current assets Current investments Inventories Trade receivables	2,261.44 2,261.44 2,485.91 81.54 969.69	324 591 888 890
(iii) (iv) (v) (vi)	Non-current investments Deferred tax assets (net) Foreign currency monetary item translation difference asset account Long-term loans and advances Other non-current assets Current assets Current investments Inventories Trade receivables Cash and cash equivalents	2,261,44 2,485,91 81,54 969,69 360,15	257 324 591 88 890 21
(iii) (iv) (v) (vi)	Non-current investments Deferred tax assets (net) Foreign currency monetary item translation difference asset account Long-term loans and advances Other non-current assets Total non-current assets Current assets Current investments Inventories Trade receivables Cash and cash equivalents Short-term loans and advances	2,261.44 2,485.91 81.54 969.69 360.15 143.27	324 591 88 890 21
(iii) (iv) (v) (vi)	Non-current investments Deferred tax assets (net) Foreign currency monetary item translation difference asset account Long-term loans and advances Other non-current assets Current assets Current investments Inventories Trade receivables Cash and cash equivalents	2,261.44 2,485.91 81.54 969.69 360.15 143.27 1,798.15	324 591 88 890 21 1111
(iii) (iv) (v) (vi)	Non-current investments Deferred tax assets (net) Foreign currency monetary item translation difference asset account Long-term loans and advances Other non-current assets Total non-current assets Current assets Current investments Inventories Trade receivables Cash and cash equivalents Short-term loans and advances	2,261.44 2,485.91 81.54 969.69 360.15 143.27	257 324 591 88 890 21

For, Global Longlife Hospital and Heleanch Dimited Dhruv Jani Managing Director DIN: 03154680

Date: 30.05.2023 Place: Ahmedabad



A division of

Global Longlife Hospital & Research LtcLobal Longlife Hospital and Research Limited

CIN: L85110GJ2012PLC068700

REGD OFFICE: GLOBAL HOSPITAL, OPP. AUDA GARDEN, NR. WATER TANK, BODAKDEV, AHMEDABAD - 380054.

AUDITED CASH FLOW STATEMENT FOR THE YEAR ENDED ON MARCH 31, 2023

	Particulars	Year Er	mount in La
		31-03-2023	31-03-2022
1	Statement of cash flows		
_	Cash flows from used in operating activities		
	Profit before extraordinary items and tax	270.78	571
2	Adjustments for reconcile profit (loss)		
	Adjustments to profit (loss)		
	Adjustments for finance costs	40.05	131
	Adjustments for depreciation and amortisation expense	116.65	114
	Adjustments for loss on sale of Fixed Asset	-	(
	Other adjustments for non-cash items	57.58	5
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	07,100	
2	Total adjustments to profit (loss)	214.28	309
3	Adjustments for working capital		
	Adjustments for decrease (increase) in inventories	6.73	(
	Adjustments for decrease (increase) in trade receivables	(78.98)	(100
	Adjustments for decrease (increase) in other assets	(3,768.51)	(10.
	Adjustments for increase (decrease) in trade payables	(296.77)	101
	Adjustments for increase (decrease) in other current liabilities	(225.14)	
	Adjustments for provisions	(24.28)	21
		(24.28)	28
	Total adjustments for working capital	(4,386.95)	15
	Total adjustments for reconcile profit (loss)	(4,172.67)	324
	Net cash flows from (used in) operations	(3,901.90)	895
	Dividends received		
_	Interest received	(3.00)	
		(9.62)	(20
	Income taxes paid (refund)	127.00	(66
	Net cash flows from (used in) operating activities before extraordinary items	(4.041.52)	0.10
	Proceeds from extraordinary items	(4,041.52)	942
	Payment for extraordinary items		
	Net cash flows from (used in) operating activities	(4,041.52)	942
4	Cash flows from used in investing activities		
	Other cash receipts from maturity of term deposits		
	Investment in Term Deposits	-	26
	Proceeds from sales of property, plant and equipment	(1.82)	
	Purchase of property, plant and equipment		1
	Dividends received	(200.44)	(47
	Interest received	3.00	
		9.18	20
_	Net cash flows from (used in) investing activities before extraordinary items	(190.08)	1
	Proceeds from extraordinary items Payment for extraordinary items		
	Net cash flows from (used in) investing activities	(190.08)	1
5	Cash flave from read in Fig. 1.		
	Cash flows from used in financing activities Proceeds from issuing shares		
	Proceeds from borrowings	4,550.00	
	Repayments of borrowings	82.11	133
	Dividends paid	(22.14)	(968
	Interest paid		
	Income taxes paid (refund)	(40.05)	(131
	Other inflows (outflows) of cash		
	Net cash flows from (used in) financing activities before extraordinary items	4.560.01	10.50
	Proceeds from extraordinary items	4,569.91	(965
	Payment for extraordinary items		
	Net cash flows from (used in) financing activities	4,569.91	(965
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	338.32	(22
5	Effect of exchange rate changes on cash and cash equivalents	330,32	(22
	Effect of exchange rate changes on cash and cash equivalents		
	Net increase (decrease) in cash and cash equivalents	338.32	(22
	Cash and cash equivalents cash flow statement at beginning of period Cash and cash equivalents cash flow statement at equivalents cash flow statement at end of period	338.32 21.83	(22. 44.

For, Global Longlife Hospital and Research Limited

Dhruv Jani Managing Director DIN: 03154680

Date: 30.05.2023 Place: Ahmedabad



Notes:

- 1) The above Financial Results which are published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at its Meeting held on 30th May, 2023.
- 2) The Financial Results have been subjected to an audit by the Statutory Auditors of the Company and they have expressed an unmodified audit opinion.
- 3) The company operates in a single segment i.e. "Medical and Healthcare Services" and hence does not have any additional disclosures to be made under AS 17 Segment Reporting.
- 4) The accompanying financial results include the results for the half year ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the first half year ended as on 30th September, 2022 of the current financial year.
 - Parallel, the accompanying financial results include the results for the half year ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year and the audited year to date figures up to the first half year ended as on 30th September, 2021 of the previous financial year
- 5) Previous period figures have been re-grouped / re-classified wherever necessary, to conform to current period's classification in order to comply with the requirements of the amended Schedule III to the Companies Act, 2013 effective 1st April 2021.
- 6) As the company is listed on SME Platform of BSE, it has been exempted from the applicability of IND-AS as per the proviso to rule 4 of companies (Indian Accounting Standards) Rules, 2015.
- 7) The Financial results have been prepared in accordance with the accounting standard as notified under section 133 of the Companies Act 2013 (Act), read with the relevant rules made thereunder and other accounting principles generally accepted in India.
- 8) During the year under review, an application for initiation of Corporate Insolvency Resolution Process ("CIRP") has been filled u/s 7 of the Insolvency and Bankruptcy Code, 2016 ("IBC") by Mr, Rajesh Agrawal for his Non-Interest bearing Unsecured Loan / deposits (known as "Quasi Equity") against the company before the Hon'ble National Company Law Tribunal (Hon'ble NCLT), Ahmedabad Bench. However, the said Application is pending Adjudication before the Hon'ble NCLT.
- 9) The results for the half year and year ended 31st March 2023 are available on the BSE Limited website (URL: www.bseindia.com) and also on the company's website (URL: www.globalhospital.co.in)

10) As the company do not have any Holding/Subsidiary/Joint Venture/Associate concern, no reporting has been made in this regard.



Independent Auditors' Report on Financial Results of GLOBAL LONGLIFE HOSPITAL AND RESEARCH LIMITED pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
The Board of Directors of
Global Longlife Hospital and Research Limited

Opinion

We have audited the accompanying Financial Results of Global Longlife Hospital and Research Limited (hereinafter referred to as the "Company") for the half year and year ended 31st March, 2023 attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"),

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial results:

- a) are presented in accordance with the Listing Regulations in this regard; and
- b) Give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other financial information for the Half and year ended 31st March, 2023.

Basis of Opinion

We conducted our audit in accordance with the Standards on Auditing ("SA") specified under Section 143(10) of the Companies Act. 2013 ("the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Annual Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act. and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our opinion.



■ Head Off.: 503, 5th Floor, "PATRON", Opp. Kensville Golf Academy, Rajpath Club to S P Ring Road,

Bodakdev, Ahmedabad - 380054 LLPIN : AAO-7574 Tel : 079 40394154 E-mail : ahd.office@karmallp.in

www.karmallp.in

AHMEDABAD SURAT MUMBAI RA

Management's and Board of Directors' Responsibilities for the Financial Results

These accompanying financial results have been prepared on the basis of the financial statements. The Company's Management and the Board of Directors are responsible for the preparation and presentation of these accompanying Half Yearly and Annual financial results that give a true and fair view of the net profit and other financial information in accordance with the recognition and measurement principles laid down in Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulation.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the accompanying Financial Results

Our objectives are to obtain reasonable assurance about whether the accompanying financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these accompanying annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the accompanying annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the accompanying financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the accompanying annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the accompanying financial results, including the disclosures, and whether the accompanying financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matters

The accompanying financial results include the results for the half year ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year and the unaudited year to date figures up to the first half year ended as on 30th September, 2022 of the current financial year.

Parallel, the accompanying financial results include the results for the half year ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year and the audited year to date figures up to the first half year ended as on 30th September, 2021 of the previous financial year.

For, KARMA & Co. LLP

Chartered Accountants

ERN No. 127544W/W100376

A Jignesh A. Dhaduk Designated Partner M.No.129149

UDIN: 23129149BGVKWE2865

Place: Ahmedabad Date: 30th May, 2023



Annexure-1

Letter No.: GLHRL/12/2022-23

Date: May 30, 2023

To, Listing Compliance Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

> SCRIPT CODE: 543520 ISIN: INE0J2K01014

Dear Sir/Madam,

Subject: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Pursuant to Regulation 33(3)(d) of the Listing Regulations, as amended from time to time, we hereby declare that Statutory Auditor of Global Longlife Hospital and Research Limited, M/s, KARMA & CO LLP., Chartered Accountants (Firm Registration Number: 127544W/W100376), have submitted their Report with unmodified opinion on the Audited Financial Results of the Company for the financial year ended March 31, 2023, as approved by the Board at its Meeting held on May 30, 2023.

Kindly please take a note for the same and do the needful.

Thanking You,

Yours Faithfully,

For, Global Longlife Hospital and Research Limited

BODAKDEV

Dhruv Jani

Managing Director

DIN: 03154680